Attorney Docket No.: 29832-0002US1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dmitry Dmitrievich Genkin et al. Art Unit: 1654

Patent No.: 7,612,032 Examiner: Christina Bradley

Issue Date: November 3, 2009 Conf. No.: 4117

Serial No.: 10/564,861

Filed: January 12, 2006

Title : METHOD FOR TREATING ONCOLOGICAL DISEASES

Attn.: Certificate of Corrections Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL OF REQUEST FOR CERTIFICATE OF CORRECTION

Applicant hereby requests that a certificate of correction be issued for the above patent in accordance with the attached request.

The claims as amended by applicant on April 30, 2009 appear in the issued patent, however, the claims as amended by Examiner's Amendment in the Notice of Allowance dated June 22, 2009 should have replaced them and been entered into the patent prior to issuance. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: June 21, 2011

Irina F. Vainberg

Reg. No. 48,008

Customer Number 26211 Fish & Richardson P.C. Telephone: (212) 765-5070 Facsimile: (877) 769-7945

30577161.doc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO.

: 7,612,032

APPLICATION NO.: 10/564,861

ISSUE DATE

: November 3, 2009

INVENTOR(S)

DMITRY DMITRIEVICH GENKIN et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 7, (colum 11, line 31) - delete "1. A method of treatment for lung carcinoma, and malignant and low differentiated lymphomia, said method comprises a step of introducing a treatment agent into a circulating blood system of a cancer patient diagnosed with at least one of the said cancers and diseases, said treatment agent destroys extracellular DNA in said blood of said cancer patient, wherein said treatment agent used to destroy said extracellular DNA is a DNAse enzyme; and wherein said treatement agent is administered in doses and regiments which provide blood plasma DNA-hydrolytic activity, - measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than 12 hours in total within 24 hours." and insert -- 1. A method of treating lung carcinoma or malignant and low differentiated lymphoma comprising parenterally administering to a patient in need thereof DNAse in doses and regimens which provide blood plasma DNA-hydrolytic activity, measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than 12 hours in total within 24 hours. --

Page 7, (colum 12, line 10) - delete "2. The method according to claim 1, wherein doses of said treatment are introduced to the patient according to a regime schedule which is carried out continuously for no less than 48 hours." and insert -- 2. The method according to claim 1, wherein said doses of DNAse are administered to the patient according to a regime schedule which is carried out continuously for no less than 48 hours. --

Page 7, (colum 12, line 14) - delete "3. The method according to claim 1, wherein bovine pancratic DNase is said agent used to destroy said extracellular DNA, said bovine pancreatic DNAsc is parenterally introduced in doses ranging from 50,000 Kunitz units to 250,000,000 Kunits units a day for 5-360 days." and insert -- 3. The method according to claim 1, wherein the DNAse is bovine pancreatic DNAse, and the dose is from 50,000 Kunitz units to 250,000,000 Kunitz units a day for 5-360 days.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Irina E. Vainberg Fish & Richardson P.C. P.O. Box 1022

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,612,032

APPLICATION NO.: 10/564,861

ISSUE DATE : November 3, 2009

INVENTOR(S) DMITRY DMITRIEVICH GENKIN et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 7, (colum 12, line 19) - delete "4. A method according to claim 1, wherein human recombinant DNAse is used." and insert -- and insert -- 4. The method according to claim 1, wherein the DNAse is human recombinant DNAse I. --

Page 7 (colum 12, line 21) - delete "5. The method according to claim 4, wherein human recombinant DNAse 1 (Domase alpha) is parenterally introduced in doses 1,15 mg/kg-500 mg/kg of body weight daily during 5-360 days." insert -- 5. The method according to claim 4, wherein the human recombinant DNAse I is administered at a dose of 0.15 mg/kg - 500 mg/kg of body weight daily for 5-360 days. --

Page 7, (colum 12, line 25) - delete "6. The method according to claim 1, wherein the treatment is carried out from a diagnosis of the cancer and to a remaining term of the patient's life." insert -- 6. The method according to claim 1, wherein the administering is carried out for the remaining term of the patient's life. --

Page 7, (colum 12, line 28) - delete "7. The method according to claim 1, further including a step of introducing a binding agent into said blood system, said binding agent binds said extracellular DNA, wherein said binding agent is anti-DNA antibodies," insert - 7. The method according to claim 1, further comprising parenterally administering to said patient anti-DNA antibodies. --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Irina E. Vainberg

Fish & Richardson P.C. P.O. Box 1022

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.